Skip to content
GH AXISFreePremiumLast updated: 2026

CJC-1295: GHRH Analogue — Complete Scientific Analysis

⚠️ The information on this page is based on scientific publications and is for educational purposes only. It does not constitute medical prescription, diagnosis, therapeutic guidance, or recommendation for use. Any clinical intervention must be individualized by a qualified healthcare professional.

Educational analysis of CJC-1295: differences between DAC and non-DAC versions, mechanism as GHRH analogue, clinical trial data from Teichman et al. (2006) and synergism with GHRP.

Mechanism of Action

CJC-1295 is a synthetic GHRH analogue with an extended half-life via DAC (Drug Affinity Complex) chemical modification. It binds to the GHRH-R receptor on somatotroph cells of the anterior pituitary, stimulating pulsatile GH release in a physiological manner.

GHRH-R Receptor Binding

CJC-1295 binds with high affinity to the GHRH receptor in the anterior pituitary. The DAC modification allows transient covalent binding to serum albumin, extending half-life from minutes (native GHRH) to 7–10 days.

cAMP/PKA Pathway Activation

Binding to Gs-coupled GHRH-R activates adenylate cyclase → cyclic AMP (cAMP) elevation → PKA activation → CREB phosphorylation → GH gene transcription and secretory vesicle exocytosis.

Hepatic IGF-1 and Anabolic Effects

Increased GH stimulates hepatic IGF-1 synthesis, mediating anabolic effects: increased muscle protein synthesis, fatty acid mobilization (lipolysis), nitrogen retention, and bone metabolism.

  • GHRH-R agonist with 7–10 day half-life (DAC version)
  • Maintains physiological pulsatile GH secretion pattern
  • Frequently combined with secretagogues like Ipamorelin for synergistic effect

Applications Described in Literature

GH Deficiency and Body Composition

Moderate evidence

Studies demonstrate that CJC-1295 significantly increases GH and IGF-1 levels. In a phase II clinical trial, weekly doses produced IGF-1 elevations of 28–43% sustained for up to 28 days, with improvements in body composition. Literature describes protocols of 1–2 mg weekly in adults with GH deficiency.

Muscle Recovery and Performance

Preliminary evidence

Via IGF-1 elevation, pre-clinical literature and case reports describe improvements in muscle recovery, protein synthesis, and visceral fat reduction. Described protocols combine CJC-1295 with Ipamorelin to amplify GH peak.

Sleep Quality and Systemic Recovery

Preliminary evidence

GH has predominant secretion during slow-wave sleep (N3). Studies with GHRH analogues demonstrate improvements in sleep architecture, with increased deep sleep. Observational literature describes benefits in systemic recovery and subjective well-being.

Relevant Studies

2 curated studies · 2005–2006

Peer-reviewed evidence with PMID verifiable on PubMed

2Randomized Clinical Trial

Latest literature review: 2026-04 · PubMed

FAQ

CJC-1295 with or without DAC — what is the difference?

CJC-1295 without DAC (also called Mod-GRF 1-29) has a half-life of ~30 minutes, producing physiological GH pulses. The DAC version (Drug Affinity Complex) binds to serum albumin, extending half-life to 6-8 days with a more continuous GH profile.

Available in Premium

Advanced scientific content locked

Premium Content

Access the Full Content

Unlock the advanced scientific guide for CJC-1295

  • Protocols described in scientific literature
  • Dose ranges observed in clinical studies
  • Associations with other peptides and supplements
  • Educational clinical comparisons
  • Monitoring and follow-up parameters
  • Educational calculators and simulators
US$ 0.25 × 10

Total: US$ 2.49

Valid for 1 year

Secure checkout via Hotmart

or get full access to all peptides

View Full Plan

⚠️ Exclusively educational content. Does not constitute medical prescription.